Related Experiment Video
Updated: Nov 25, 2025
06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.6K
COX-2 Overexpression in Schneiderian Papillomas
Jeffrey D Suh1, Kevin Hur2,3, Elisabeth H Ference2
1Department of Head and Neck Surgery, University of California, Los Angeles, California.
Allergy & Rhinology (Providence, R.I.)
|December 21, 2020
Summary
Cyclo-oxygenase-2 (COX-2) is overexpressed in Schneiderian papillomas (SP), an aggressive sinonasal tumor. This finding suggests COX-2 may be a potential therapeutic target for SP treatment.
Area of Science:
- Oncology
- Otorhinolaryngology
- Molecular Biology
Background:
- Schneiderian papillomas (SP) are aggressive sinonasal tumors.
- SP can extend into surgically unresectable areas.
Purpose of the Study:
- To evaluate the significance of cyclo-oxygenase-2 (COX-2) expression in SP.
- To determine if COX-2 expression correlates with SP characteristics or recurrence.
Main Methods:
- Immunohistochemistry for COX-2 was performed on 67 SP samples and 9 control samples.
- A positive COX-2 stain was defined as ≥10% of cells exhibiting diffuse immunoreactivity.
- Statistical comparisons included Fisher Exact tests, t-tests, and ANOVA.
Main Results:
- COX-2 was overexpressed in 58.2% of SP cases (15 strongly positive, 24 weakly positive).
- No positive COX-2 staining was observed in the control group (p < 0.01).
- No significant differences in COX-2 expression were found based on gender, smoking history, previous surgery, tumor site, subtype, or recurrence.
Conclusions:
- COX-2 is significantly overexpressed in Schneiderian papillomas.
- The role of COX-2 in SP progression and recurrence requires further investigation.
- COX-2 may represent a potential therapeutic target for SP.
